ssr-list | Orexo

17 July 2024 at 08:00 – Regulatory – Report – Q2

Orexo Q2 2024 Interim Report

16 July 2024 at 20:00 – Regulatory

Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose

10 July 2024 at 08:00

Orexo AB´s sustainability work ranked among top 5% by EcoVadis

8 July 2024 at 14:00

Orexo: invitation to presentation of the Q2 2024 Interim Report

10 May 2024 at 13:30

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

8 May 2024 at 08:00 – Regulatory – Report – Q1

Orexo Q1 2024 Interim Report

7 May 2024 at 10:30

Fentanyl awareness day: The synthetic opioid fentanyl increasingly poisons young Americans

2 May 2024 at 09:00

Invitation to presentation of Orexo´s Q1 2024 Interim Report

26 April 2024 at 17:30 – Regulatory – General Meeting

Report from Orexo AB’s annual general meeting, 26 April 2024

17 April 2024 at 08:00

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

2 April 2024 at 13:15

Orexo announces that the condition for early redemption of its existing bonds has been fulfilled

28 March 2024 at 08:00 – Regulatory – Report

Orexo publishes the Annual and Sustainability Report for 2023

15 March 2024 at 18:30 – Regulatory – General Meeting

Correction: Notice of Annual General Meeting of Orexo

15 March 2024 at 10:00 – Regulatory – General Meeting

Notice of Annual General Meeting of Orexo

13 March 2024 at 20:30 – Regulatory

Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds

8 March 2024 at 14:30

Leading with purpose: Why Cecilia Coupland became an Orexo executive

8 March 2024 at 08:10

Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds

8 March 2024 at 08:00

Orexo strengthens its sustainability work by establishing a social financing framework

12 February 2024 at 08:00

Orexo and Sobi agree to advance feasibility study with AmorphOX

8 February 2024 at 08:00 – Regulatory – Report – Q4

Orexo Interim Report Q4 2023, incl. Full Year Report

6 February 2024 at 08:00

Orexo’s OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC

30 January 2024 at 13:15

Invitation to presentation of Orexo´s Full Year Report 2023

28 November 2023 at 08:00

Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose

2 November 2023 at 08:00 – Regulatory – Report – Q3

Orexo Q3 2023 Interim Report

27 October 2023 at 08:00